The CDK4/6 inhibitors, palbociclib (PD-0332991), ribociclib, and abemaciclib, in combination with endocrine therapy are frequently used to treat recurrent ERα+ breast cancer and have improved progression free survival (PFS) [142,143]. This evidence concerns the gene ESR1 and breast carcinoma.